Claims
- 1. In a therapeutic composition for topical treatment of ocular hypertension or glaucoma containing a prostaglandin PGA, PGB, PGE or PGF in an amount sufficient to reduce intraocular pressure without causing substantial ocular irritation and an ophthalmologically compatible vehicle, the improvement comprising the omega chain of the prostaglandin having the formula
- C.sub.13 --B--C.sub.14 --D.sub.15-24 --R.sub.2
- wherein
- C is a carbon atom (the number according to standard prostaglandin nomenclature being indicated by the subscript);
- B is a single bond, a double bond, or a triple bond;
- D represents a sub-chain of 1-10 carbon atoms with 1-2 heteroatoms selected from the group that consisists of N, and S, with substituents on each carbon atom that are selected from the group consisting of a hydrogen atom, an alkyl group, an oxo group and a hydroxyl group, and
- an cycloalkyl or cycloalkenyl ring structure, with 3-7-carbon atoms in the ring, which is
- (1) unsubstituted or
- (2) substituted with at least one lower alkyl group containing 1-5 carbon atoms.
- 2. A composition according to claim 1 in which, in the omega chain of the prostaglandin, R.sub.2 is a cyclohexyl group.
- 3. A Method of treating glaucoma or ocular hypertension by topical application of the therapeutic composition of claim 1.
- 4. A method of treating glaucoma or ocular hypertension by topical application of the therapeutic composition of claim 2.
- 5. A therapeutic composition for topical treatment of ocular hypertension or glaucoma, containing a prostaglandin PGA, PGB, PGE, or PGF in an amount sufficient to reduce intraocular pressure without causing substantial ocular irritation and an ophthalmologically compatible vehicle, in which the alpha chain of the prostaglandin comprises a chain of 6 to 10 carbon atoms, which is either
- (a) saturated or
- (b) unsaturated having one or more non-cummulated double bonds, or a triple bond,
- the alpha chain being
- c) unsubstituted or
- d) substituted with one or more substituents selected from the group of alkyl groups, alicyclic rings, aromatic rings or heteroaromatic rings,
- and in which the omega chain of the prostaglandin has the formula
- C.sub.13 --B--C.sub.14 --D.sub.15-24 --R.sub.2
- wherein
- C is a carbon atom (the number according to standard prostaglandin nomenclature being indicated by the subscript);
- B is a single bond, a double bond, or a triple bond;
- D represents a sub-chain of 1-10 carbon atoms and 1-2 heteroatoms selected from the group that consists of O, N, and S, with substituents on each sub-chain atom that are selected from the group consisting of a hydrogen atom, an alkyl group, an oxo group and a hydroxyl group, and
- R.sub.2 is a cycloalkyl or cycloalkyenyl ring of 3 to 7 carbon atoms, which is unsubstituted or substituted with at least one lower alkyl substituent of 1-5 carbon atoms.
- 6. A composition according to claim 5 in which, in the omega chain of the prostaglandin, R.sub.2 is a cyclohexyl group.
- 7. A method of treating ocular hypertension or glaucoma by topical application of the therapeutic composition of claim 5.
- 8. A method of treating ocular hypertension or glaucoma by topical application of the therapeutic composition of claim 6.
Priority Claims (3)
Number |
Date |
Country |
Kind |
8803110 |
Sep 1988 |
SEX |
|
880385 |
Oct 1988 |
SEX |
|
PCT/SE89/00475 |
Sep 1989 |
WOX |
|
Parent Case Info
This application is a continuation of application Ser. No. 07/986,943 filed on Dec. 8, 1992, now U.S. Pat. No. 5,422,368 which is a continuation of Ser. No. 07/469,442 filed on Apr. 10, 1990 now abandoned.
US Referenced Citations (20)
Foreign Referenced Citations (1)
Number |
Date |
Country |
573018 |
Feb 1986 |
AUX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
986943 |
Dec 1992 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
469442 |
Apr 1990 |
|